Biotech IV Monitor

DNTH — Dianthus Therapeutics Inc.

$5.7B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Dianthus Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts32 Phase 3
Market cap$5.7B
Cash & investments$1.24B~27 quarters at last loss rate
Recent 8-K filings1latest 2026-11-04

Upcoming readouts

Phase 2 Claseprubart
Multifocal Motor Neuropathy · NCT06537999
December 2026
Ongoing
Phase 3 Claseprubart
Myasthenia Gravis, Generalized · NCT07647510
December 2028
Recruiting
Phase 3 Claseprubart
Chronic Inflammatory Demyelinating Polyneuropathy · NCT06858579
December 2028
Recruiting

Cash position

Dianthus Therapeutics Inc. reported $1.24B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $47M; at that rate the cash would last about 27 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04

Companies working on similar indications

Discussion

No messages yet. If you follow DNTH, you can start the conversation.
Track DNTH in real time
See live implied volatility for DNTH and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on DNTH
Contact — questions or corrections about DNTH: dukeupt@gmail.com